TerminatedNo phase

Connect® Myeloid Disease Registry

Reason given: Business objectives have changed

Key facts

Where: Abilene, Akron, Amarillo, Ames, Anderson, Ann Arbor, Augusta, Bakersfield, Bellingham, Berkeley, Bethesda, Billings, Bloomington, Boise, Bolivar, Boynton Beach, Brunswick, Cape Girardeau, Chicago, Christiana, Cleveland, Columbia, Columbus, Concord, Cooperstown, Covington, Cumberland, Dallas, Daytona Beach, Denver, Detroit, Duluth, Dunmore, East Syracuse, Edina, Evanston, Everett, Fayetteville, Flint, Fort Lauderdale, Fresno, Gainesville, Garden City, Grand Rapids, Green Bay, Greenville, Grosse Pointe Woods, Hackensack, Harvey, Huntington Station, Hyannis, Jacksonville, Johnson City, Joliet, Jonesboro, Joplin, Kansas City, Kennewick, Kinston, Knoxville, La Crosse, La Jolla, Lafayette, Lakeland, Lancaster, Lansing, Laredo, Lincoln, Lubbock, Lynchburg, Manchester, Marietta, McAllen, Memphis, Milwaukee, Monterey, Morgantown, Nashville, New Brunswick, New York, Newport News, Ocala, Ogden, Oklahoma City, Olympia, Orlando, Paterson, Pembroke Pines, Pensacola, Peoria, Phoenix, Portland, Providence, Quincy, Racine, Rochester, Roslyn, Round Rock, Saint Joseph, Saint Louis Park, Salem, San Diego, Santa Rosa, Seattle, Sioux City, Skokie, Somerville, Sparta, Spartanburg, Springfield, St Louis, Stamford, Stockton, Temple, The Bronx, Toledo, Topeka, Tucson, Tulsa, Tuscaloosa, Valhalla, Walla Walla, Watertown, Waukesha, West Reading, Westminster, White River Junction, Wichita, and York, United StatesSee the 154 sites

Where in United States

Hendrick Cancer CenterAbilene, United StatesNo longer taking part
Summa Health SystemAkron, United StatesNo longer taking part
Texas Oncology - Amarillo Cancer CenterAmarillo, United StatesNo longer taking part
McFarland Clinic, P.C.Ames, United StatesNo longer taking part
St. Vincent Anderson Regional Hospital ResearchAnderson, United StatesNo longer taking part
University of Michigan Health System (UMHS) - University Hospital (University of Michigan Medical CeAnn Arbor, United StatesNo longer taking part
Georgia Regents University Cancer CenterAugusta, United StatesNo longer taking part
Comprehensive Blood & Cancer CenterBakersfield, United StatesNo longer taking part
PeaceHealth St Joseph Cancer CenterBellingham, United StatesNo longer taking part
Alta Bates Summit Comprehensive CancerBerkeley, United StatesNo longer taking part
Sutter East Bay Hospitals (dba Jordan Research and Education Institute - REDI)Berkeley, United StatesNo longer taking part
Center for Cancer and Blood DisordersBethesda, United StatesNo longer taking part
St. Vincent Frontier Cancer CenterBillings, United StatesNo longer taking part
IU Health Bloomington HospitalBloomington, United StatesNo longer taking part
Saint Alphonsus Regional Medical CenterBoise, United StatesNo longer taking part
MCDA - Central Care CenterBolivar, United StatesNo longer taking part
University Cancer InstituteBoynton Beach, United StatesNo longer taking part
Southeast Georgia Health SystemBrunswick, United StatesNo longer taking part
Southeast Cancer CenterCape Girardeau, United StatesNo longer taking part
Rush University Cancer CenterChicago, United StatesNo longer taking part
Delaware Clinical and Laboratory PhysiciansChristiana, United StatesNo longer taking part
ClevelandCleveland, United StatesNo longer taking part
Cleveland Clinic FoundationCleveland, United StatesNo longer taking part
University Hospitals Case Medical CenterCleveland, United StatesNo longer taking part
Boone Hospital CenterColumbia, United StatesNo longer taking part
Harry S. Truman Memorial Veterans' HospitalColumbia, United StatesNo longer taking part
Maryland Oncology HematologyColumbia, United StatesNo longer taking part
Columbus Regional Research InstituteColumbus, United StatesNo longer taking part
Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister CenterColumbus, United StatesNo longer taking part
John Muir Clinical Research CenterConcord, United StatesNo longer taking part
Bassett Heathcare NetworkCooperstown, United StatesNo longer taking part
Mary Bird Perkins Cancer Center at St. TammanyCovington, United StatesNo longer taking part
QCCA - Pontchartrain Cancer CenterCovington, United StatesNo longer taking part
Western Maryland Health SystemCumberland, United StatesNo longer taking part
Dallas VA Medical CenterDallas, United StatesNo longer taking part
HOLD - Texas Oncology, DallasDallas, United StatesNo longer taking part
Texas Oncology Sammons Cancer CenterDallas, United StatesNo longer taking part
Halifax Health Center for OncologyDaytona Beach, United StatesNo longer taking part
Saint Joseph Hospital - Cancer Centers of ColoradoDenver, United StatesNo longer taking part
Henry Ford Health SystemDetroit, United StatesNo longer taking part
John D. Dingell VA Medical Center /Cynthia MarburyDetroit, United StatesNo longer taking part
Essentia Health Oncology Clinical TrialsDuluth, United StatesNo longer taking part
Hematology and Oncology Assoc of NEPADunmore, United StatesNo longer taking part
Hematology Oncology Associates of Central NYEast Syracuse, United StatesNo longer taking part
Southdale Cancer ClinicEdina, United StatesNo longer taking part
Northshore University Health SystemEvanston, United StatesNo longer taking part
Providence Regional Cancer PartnershipEverett, United StatesNo longer taking part
Highlands Oncology GroupFayetteville, United StatesNo longer taking part
Genesys Hurley Cancer InstituteFlint, United StatesNo longer taking part
Holy Cross HospitalFort Lauderdale, United StatesNo longer taking part
VA Central California Health Care SystemFresno, United StatesNo longer taking part
University of FloridaGainesville, United StatesNo longer taking part
Central Care Cancer CenterGarden City, United StatesNo longer taking part
Cancer and Hematology Centers of Western MichiganGrand Rapids, United StatesNo longer taking part
Bellin Memorial Hospital/ Bellin Cancer TeamGreen Bay, United StatesNo longer taking part
St Vincent HospitalGreen Bay, United StatesNo longer taking part
Leo W Jenkins Cancer CenterGreenville, United StatesNo longer taking part
Prisma Health Cancer Institute - UpstateGreenville, United StatesNo longer taking part
Ascension St. John Hospital_Hematology (was St. Johns Hospital and Hematology-Oncology Associates East PC)Grosse Pointe Woods, United StatesNo longer taking part
John Theurer Cancer Center (Hackensack U Med Center)Hackensack, United StatesNo longer taking part
Ingalls Memorial HospitalHarvey, United StatesNo longer taking part
Huntington Medical GroupHuntington Station, United StatesNo longer taking part
Cape Cod HospitalHyannis, United StatesNo longer taking part
Cancer Specialists of North FloridaJacksonville, United StatesNo longer taking part
Johnson CityJohnson City, United StatesNo longer taking part
JolietJoliet, United StatesNo longer taking part
Joliet Oncology Hematology Associates LtdJoliet, United StatesNo longer taking part
JonesboroJonesboro, United StatesNo longer taking part
Clopton Clinic of Jonesboro, Inc.Jonesboro, United StatesNo longer taking part
NEABC- Fowler Family Center for Cancer CareJonesboro, United StatesNo longer taking part
Mercy Cancer Center - JoplinJoplin, United StatesNo longer taking part
Kansas City Veterans Affairs Medical CenterKansas City, United StatesNo longer taking part
Kadlec Regional Medical Center (KRMC)Kennewick, United StatesNo longer taking part
Kinston Medical SpecialistsKinston, United StatesNo longer taking part
Thompson Cancer Survival CenterKnoxville, United StatesNo longer taking part
University of Tennessee Medical Center Cancer IntituteKnoxville, United StatesNo longer taking part
Gundersen Lutheran IncLa Crosse, United StatesNo longer taking part
UCSD Moores Cancer CenterLa Jolla, United StatesNo longer taking part
Horizon Oncology Research, Inc.Lafayette, United StatesNo longer taking part
Watson Clinic Center for Cancer Care and ResearchLakeland, United StatesNo longer taking part
Lancaster Cancer CenterLancaster, United StatesNo longer taking part
Lancaster General HospitalLancaster, United StatesNo longer taking part
Michigan State University, Breslin Cancer CenterLansing, United StatesNo longer taking part
Oncology and Hematology of South Texas, PALaredo, United StatesNo longer taking part
Southeast Nebraska Cancer CenterLincoln, United StatesNo longer taking part
Southwest Cancer Treatment & Research CenterLubbock, United StatesNo longer taking part
Lynchburg Hematology-Oncology ClinicLynchburg, United StatesNo longer taking part
Regional Cancer Care AssociatesManchester, United StatesNo longer taking part
VA Medical Center ManchesterManchester, United StatesNo longer taking part
Northwest Georgia Oncology Centers, P.C.Marietta, United StatesNo longer taking part
Texas Oncology, McAllen (plus 2 satelite sites)McAllen, United StatesNo longer taking part
Regional One HealthMemphis, United StatesNo longer taking part
Columbia St. Mary'SMilwaukee, United StatesNo longer taking part
Pacific Cancer CareMonterey, United StatesNo longer taking part
West Virginia UniversityMorgantown, United StatesNo longer taking part
Vanderbilt-Ingram Cancer CenterNashville, United StatesNo longer taking part
Saint Peter's University HospitalNew Brunswick, United StatesNo longer taking part
Weill Cornell Medical CollegeNew York, United StatesNo longer taking part
Peninsula Cancer InstituteNewport News, United StatesNo longer taking part
Ocala OncologyOcala, United StatesNo longer taking part
Community Cancer Trials of UtahOgden, United StatesNo longer taking part
INTEGRIS Cancer Institute of Oklahoma Proton CampusOklahoma City, United StatesNo longer taking part
INTEGRIS Cancer Institute Southwest Medical CenterOklahoma City, United StatesNo longer taking part
Vista Oncology Inc PSOlympia, United StatesNo longer taking part
Adventist Health System/Sunbelt, Inc.Orlando, United StatesNo longer taking part
St Joseph Healthcare SystemPaterson, United StatesNo longer taking part
Memorial Healthcare SystemPembroke Pines, United StatesNo longer taking part
Sacred Heart Medical Oncology GroupPensacola, United StatesNo longer taking part
Illinois Cancer CarePeoria, United StatesNo longer taking part
Arizona OncologyPhoenix, United StatesNo longer taking part
PortlandPortland, United StatesNo longer taking part
Providence Cancer CenterPortland, United StatesNo longer taking part
Roger Williams Medical CenterProvidence, United StatesNo longer taking part
Quincy Medical GroupQuincy, United StatesNo longer taking part
Wheaton Franciscan Cancer Care - All SaintsRacine, United StatesNo longer taking part
Rochester General HospitalRochester, United StatesNo longer taking part
St. Francis HospitalRoslyn, United StatesNo longer taking part
Scott & White HealthcareRound Rock, United StatesNo longer taking part
Heartland Regional Medical Center (Heartland Health)Saint Joseph, United StatesNo longer taking part
Metro MN CCOP/Park Nicollet InstituteSaint Louis Park, United StatesNo longer taking part
Salem HealthSalem, United StatesNo longer taking part
San DiegoSan Diego, United StatesNo longer taking part
Santa RosaSanta Rosa, United StatesNo longer taking part
Benaroya Research Institute at Virginia MasonSeattle, United StatesNo longer taking part
Swedish Cancer InstituteSeattle, United StatesNo longer taking part
Siouxland Hematology Oncology AssociatesSioux City, United StatesNo longer taking part
Edward H. Kaplan MD & AssociatesSkokie, United StatesNo longer taking part
Orchard Healthcare Research Inc.Skokie, United StatesNo longer taking part
Somerset Medical Center 110 Rehill AvenueSomerville, United StatesNo longer taking part
Sparta Cancer CenterSparta, United StatesNo longer taking part
Spartanburg Regional Medical CenterSpartanburg, United StatesNo longer taking part
Mercy Research - SpringfieldSpringfield, United StatesNo longer taking part
Simmons Cancer Institute at Southern Illinois UniversitySpringfield, United StatesNo longer taking part
St LouisSt Louis, United StatesNo longer taking part
Missouri Baptist Medical CenterSt Louis, United StatesNo longer taking part
Bennett Cancer Center Stamford HospitalStamford, United StatesNo longer taking part
St. Joseph's Regional Cancer CenterStockton, United StatesNo longer taking part
Baylor Research Institute dba Scott & White Memorial HospitalTemple, United StatesNo longer taking part
New York Cancer and Blood SpecialistsThe Bronx, United StatesNo longer taking part
University of Toledo Medical Center (Utmc)Toledo, United StatesNo longer taking part
Cotton O'Neil Clinical Research/ Stormont Vail HealthTopeka, United StatesNo longer taking part
TucsonTucson, United StatesNo longer taking part
The University of Arizona Cancer CenterTucson, United StatesNo longer taking part
Oklahoma Cancer Specialist and Research InstituteTulsa, United StatesNo longer taking part
DCH Health System (Lewis and Faye Manderson Cancer Center)Tuscaloosa, United StatesNo longer taking part
New York Medical CollegeValhalla, United StatesNo longer taking part
Providence St. Mary Regional Cancer CenterWalla Walla, United StatesNo longer taking part
Prairie Lakes Health Systen, IncWatertown, United StatesNo longer taking part
Waukesha Memorial HospitalWaukesha, United StatesNo longer taking part
Reading Hospital - McGlinn Cancer InstituteWest Reading, United StatesNo longer taking part
Carroll Regional Cancer CenterWestminster, United StatesNo longer taking part
VA Medical Center - White River JunctionWhite River Junction, United StatesNo longer taking part
Cancer Center of KansasWichita, United StatesNo longer taking part
Cancer Care Associates of YorkYork, United StatesNo longer taking part

Trial details

Who runs it: Celgene
Trial code: NCT01688011
Record updated: 3 July 2025
Original description: The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.Read full original descriptionShow less
Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Inclusion: Patients must be able to provide written informed consent form (ICF); Must be willing and able to complete baseline and follow-up HRQoL instruments, for which patients must be proficient in either English or Spanish; AML patients must be at least 55 years of age at the time of informed consent; MF, ICUS, and MDS patients must be at least 18 years of age at the time of informed consent; Newly diagnosed Idiopathic Cytopenias of Undetermined Significance (ICUS), Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) patients:; Newly diagnosed primary or secondary disease. To be considered "newly diagnosed", a patient's confirmed diagnosis must be made no more than 60 days prior to the date of consent signature. (An additional 5-day window [i.e., up to 65 days prior to the date of ICF signature] may be allowed in special circumstance upon sponsor approval); Cohort assignment confirmed by central eligibility review. Cohort assignment must also be confirmed by the site; Myelofibrosis (MF) patients:; Patients who initiated their first active systemic treatment for MF and/or MF-related cytopenias within 90 days prior to the date of consent signature. This cohort allows the enrollment of subjects with a diagnosis of Myelodysplastic/Myeloproliferative overlap syndromes (MDS/MPN overlap syndrome); Cohort assignment is confirmed by the site. Central eligibility review is not required; Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS) patients:; Patients who have initiated first active treatment regimen containing at least one non-ESA therapy, within 90 days prior to ICF; Cohort assignment is confirmed by site. Central eligibility review is not required; Luspatercept treated patients:; Patient must have been at least 18 years of age at the start of luspatercept; Among LR-MDS patients, patient must have initiated luspatercept on or after September 1, 2023, must be ESA-naïve and luspatercept must be the first active treatment (as monotherapy or part of a treatment regimen) for their disease; Among all other myeloid malignancies, there is no date restriction for initiation of luspatercept .Patient may have received prior treatment for their disease; Patient must have at least 3 months of follow-up from start of luspatercept treatment at the participating site.
Exclusion: Currently enrolled in any interventional clinical trial where the patient is being treated with an investigational product that cannot be identified; Idiopathic Cytopenias of Undetermined Significance (ICUS), Myelodysplastic Syndromes (MDS) patients who received or are receiving active (disease modifying) therapy for the treatment of MDS prior to the date of informed consent; Acute Myeloid Leukemia (AML) patients who initiated active (disease modifying treatment for AML more than 2 weeks prior to the date of consent; Patient must not be currently or previously enrolled in the Connect Myeloid Registry; Patient must not have received luspatercept as part of a clinical trial; Myelofibrosis (MF) and Myelodysplastic/Myeloproliferative (MDS/MPN) overlap syndrome patients with suspected juvenile myelomonocytic leukemia (JMML); Luspatercept treated patients:; Suspected or proven acute promyelocytic leukemia (APL) (FAB M3 or WHO 2008) based on morphology, immunophenotype, molecular assay or karyotype.
ClinicalTrials.gov NCT01688011